BioInvent International AB

BIOI-B.ST

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 30, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
pembrolizumab (KEYTRUDA®)	Phase 2	Melanoma Metastatic	-
BI-1808	Phase 2	Advanced Malignancies	-
BI-1910	Phase 2	Solid Tumors	-
BI-1206	Phase 2	Indolent B-Cell Non-Hodgkin Lymphoma	-
BI1206	Phase 2	Solid Tumor, Adult	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

Dec 30, 2025pembrolizumab (KEYTRUDA®)

Primary completion for pembrolizumab (KEYTRUDA®) trial (NCT06784648) in Melanoma Metastatic

Phase 2

Sep 30, 2026BI-1206

Primary completion for BI-1206 trial (NCT03571568) in Indolent B-Cell Non-Hodgkin Lymphoma

Regulatory Approvals

BIOI-B.ST News